News Daily News Peer Coaching May Help With BP Control in Rural Black Populations Todd Neale March 22, 2024
News Daily News When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters Yael L. Maxwell March 21, 2024
News Daily News FDA Approves Aprocitentan for Inadequately Controlled Hypertension Michael O'Riordan March 20, 2024
News Daily News LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play Todd Neale March 15, 2024
News Conference News THT 2024 Smart Scale Better at Predicting HF Events Than Weight-Based Monitoring Michael O'Riordan March 11, 2024
News Daily News ACC Updates HFrEF Decision Pathway, Reinforcing the Four Pillars of Therapy Todd Neale March 11, 2024
News Conference News CRT 2024 Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis L.A. McKeown March 09, 2024
News Conference News THT 2024 Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF Michael O'Riordan March 08, 2024
News Daily News Patients With CKD Remain Underrepresented in Trials of CV Meds Todd Neale March 08, 2024
News Conference News THT 2024 Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients Michael O'Riordan March 07, 2024
News Conference News THT 2024 Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS Michael O'Riordan March 06, 2024
News Conference News THT 2024 Debating the Role of T-TEER in the Sickest Patients Michael O'Riordan March 05, 2024
News Daily News Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial Todd Neale March 04, 2024
News Daily News DISCHARGE Data Reassure on Use of CCTA in Older Chest-Pain Patients Michael O'Riordan March 04, 2024
News Daily News High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention Michael O'Riordan February 29, 2024
News Daily News High Lp(a) Levels Harmful in Patients With and Without ASCVD Michael O'Riordan February 27, 2024
News Daily News One in Three Overweight MI Patients May Benefit From Semaglutide Todd Neale February 26, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024